Fulcrum Therapeutics (FULC) Receivables (2020 - 2024)

Fulcrum Therapeutics (FULC) has 5 years of Receivables data on file, last reported at $2.1 million in Q4 2024.

• Receivables for Q4 2024 came in at $2.1 million, up 290.32% year-over-year; the trailing twelve-month figure through Dec 2024 was $2.1 million (up 290.32% YoY), and the FY2024 annual result was $2.1 million, up 290.32% from the prior year.
• Receivables rose to $2.1 million in Q4 2024 per FULC's latest filing, from $537000.0 in the prior quarter.
• Over five years, Receivables peaked at $3.6 million in Q4 2021 and troughed at $113000.0 in Q3 2022.
• A 5-year average of $1.2 million and a median of $729000.0 in 2022 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2023: Receivables tumbled 93.7% in 2022, then surged 413.27% in 2023.
• A 5-year view of Receivables shows it stood at $2.0 million in 2020, then jumped by 81.85% to $3.6 million in 2021, then plunged by 93.7% to $229000.0 in 2022, then soared by 134.5% to $537000.0 in 2023, then jumped by 290.32% to $2.1 million in 2024.
• Business Quant data shows FULC's Receivables at $2.1 million in Q4 2024, $537000.0 in Q4 2023, and $580000.0 in Q3 2023.